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Abstract
Detrusor muscle overactivity in the bladder wall is the hallmark symptom of overactive
bladder syndrome and the principal target of therapy that seeks to reduce incontinence and
urinary urgency. However, these interventions typically fail to alleviate long-term detrusor
overactivity and simply mask the underlying pathology while also potentially introducing
undesirable side effects that disrupt quality of life. One alternative mechanism driving of
overactive bladder is attributed to ischemia within the bladder, which is subject to
enormous swings in pressure and tension on its vasculature restricting blood flow. This
observation, coupled with the fact that healthy vascular tissue within the bladder lacks a
myogenic response to increasing intraluminal pressures, provides a potential pathological
explanation and new therapeutic targets for managing overactive bladder. We evaluated
whether conscious voiding behavior in mice is impacted with the introduction of myogenic
tone into the bladder vasculature via knock out of the inward-rectifier potassium channel,
KIR2.1. The voiding activity of 10 smooth muscle-specific tamoxifen-inducible KIR2.1
knockout mice were observed pre- and post-tamoxifen treatment using the UroVoid
System: a novel apparatus for measuring micturition events in real time. A consistent
difference of voiding behavior between knockout and control treatment groups could not
be demonstrated. However, voiding frequency of all mice within the trials are elevated
above established literature values as well as prior trials of different mice within the
UroVoid. Absent controls and potential confounding factors from the environment in
which the trials take place obscured a definitive conclusion from the data while
emphasizing the importance of comprehensive environmental vetting and strict protocol
adherence prior to conducting UroVoid experiments. Thus, future experiments can still
effectively test the role of KIR2.1 channels in bladder health as long as the confounding
factors are accounted for.
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Introduction
Overactive bladder syndrome (OAB) is a prevalent condition in which people
experience urinary urgency due in part to involuntary bladder contractions. This can lead
to a range of symptoms including urinary frequency, nocturia, and urge incontinence[8].
Although it is not characterized as a lethal pathology, the negative impacts on mental
health, reduced sleep, and poor quality of life contribute to significant social strain. A 2007
estimate of $66 billion in total costs for management of OAB in US populations illustrates
that this condition has serious impacts on healthcare systems as well as other sectors in lost
productivity[9]. Roughly 16% of both men and women experience OAB, although there
are differences between sexes with the presentation of urge incontinence affecting women
more readily[8]. OAB occurs across all age groups and prevalence increases with age[8].
Despite all of this, the urinary bladder and its associated pathologies have historically been
under-researched and many physiological processes key to regulation of normal bladder
function remain poorly understood.
Patients with OAB present a challenge to physicians because no single current
therapy is particularly effective. The initial encounter with OAB is first managed with “best
supportive care” (BSC) consisting of incontinence pads, behavioral coaching, and if
necessary, intermittent self-catheterization[10]. Behavioral coaching attempts to engage
the patient in actions that either reduce urine production by examining diet and fluid intake
or strengthen voluntary muscles involved in urine retention with pelvic floor exercises.
Although always recommended as a conservative treatment approach, long-term outcomes
of BSC management alone are questionable, leading many providers to aggressively target
involuntary bladder contractions with medications[11].
1

Pharmacotherapy and nerve stimulation techniques classically target bladder
contraction itself with known drug targets within the detrusor smooth muscle. The theory
is that OAB symptoms are caused by over-excitability of the detrusor muscle; thus, by
relaxing the detrusor the bladder can fill for longer and delay the feeling of urgency and
reducing the frequency of urination. These drugs include first-line antimuscarinics
typically coupled with behavioral therapy and fluid management. However, patient
compliance to this medication regimen has been a consistent problem, with many
discontinuing their use of antimuscarinics due to unpleasant side effects and/or poor
efficacy[12]. Additional treatments include the β3 adrenergic agonist mirabegron,
onabotulinumtoxinA (BOTOX®) injection, and surgical interventions (such as
percutaneous tibial nerve stimulation and implantable sacral nerve stimulation), with no
clearly superior treatment option and no clear treatment progression for physicians to
follow[10]. All of the above treatments (with the exception of fluid management) operate
on the suppression of detrusor muscle “overactivity” without addressing the underlying
cause behind the feeling of urgency. These treatments also often result in urinary retention
because the bladder is not able to sufficiently contract to properly void urine when needed.
In this case, patients have exchanged one set of symptoms for a far more dangerous one:
unchecked urinary retention can lead to frequent infection, vesicourethral reflux, and
kidney failure[13]. This leaves a significantly untapped area of research and drug
development for OAB management. Understanding the pathology of detrusor overactivity,
whether it is due to inflammation, hypoxia, neurologic factors, or some combination
therein, will allow for more efficacious and targeted strategies in addressing the underlying
causes of OAB and not just the symptoms.
2

In our research, we attempted to elucidate the implications of inadequate blood flow
and bladder tissue ischemia in the development of OAB. As a hollow organ that frequently
fills and empties with fluid, the bladder has multiple specialized adaptions that serve to
maintain adequate tissue perfusion during distention. Our focus is on the myogenic
response characteristics of the bladder vasculature, which differs from multiple other tissue
types. In an effort to prevent fluctuations in arterial pressure from being transmitted
downstream to the capillary bed and causing tissue damage, small blood vessels in other
areas of the body exhibit “myogenic tone” (i.e., constriction in response to increases in
intraluminal pressure) [14]. An integral component of mediating this response are the
strong inward-rectifying K+ channels (KIR), which serve to maintain resting membrane
potential in smooth muscle cells and endothelial cells of arterioles from many
myogenically-active vascular beds [15]. Our previous work discovered that a specific
inward-rectifying K+ channel, KIR2.1, is expressed in the smooth muscle of the bladder
microvasculature where it is able to completely prevent vessel constriction in response to
increases in intraluminal pressure[1]. Removal or inhibition of these channels results in
“restored” myogenic tone[1], a status that is physiologically normal in many other tissues
such as the brain, kidneys, and retina[16-18], but less than ideal in the bladder vasculature.
Under normal conditions, these vessels seem to completely lack myogenic tone in
an effort to maintain bladder wall blood flow as these vessels are stretched and compressed
during bladder filling (Figure 1). Were these vessels to develop myogenic tone, the
increasing intraluminal pressure caused by vessel compression as the bladder wall stretched
would feed forward, leading to more vessel constriction and bladder ischemia, which
results in increased detrusor activity and frequent voiding [19]. This suggests that changes
3

in blood flow alone can be responsible for the development of symptoms of OAB. Thus,
by preventing constriction of the bladder vasculature to alleviate tissue ischemia, OAB
symptoms may be able to be treated without impairing detrusor muscle contractility or
causing urinary retention.

Fig 1. Change in Vascular Shape and Diameter During Bladder Filling. Physical adaptions, such
as vessel coiling and elastin sheathing, maintain vessel diameter initially until distention begins to
compress the vessel and likely resulting in acute ischemia of the surrounding tissue.
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Anatomy & Physiology of the Urinary Bladder
As a muscular hollow organ, the bladder serves as an interim storage vessel for
urine produced by the kidneys. Distending as it fills, the typical human bladder capacity is
300-400 ml in a healthy adult with normal voiding behavior[20]. The bladder sits on the
pelvic floor inferior to the kidneys, which feed urine to the bladder via two ureters. The
ureters connect at the neck of the bladder to form the trigone together with the internal
urethral orifice. Vesicourethral reflux of urine into the ureters is prevented by mucosal
flaps, thus ensuring collecting urine will distend the body of the bladder upwards until
voiding. The apex of the bladder located anteriorly is connected to the abdominal wall via
the median umbilical ligament. As it fills, the bladder predominantly expands its volume
by distention of an elastic fundus lined with interior rugae from the top of the body. Healthy
adult bladder wall thickness is approximately 3 mm when not distended and becomes much
thinner during filling[21]. The cone-like shape of the bladder funnels urine toward the
internal urethral sphincter. The sphincter relaxes in coordination with detrusor contraction
within the bladder wall to encourage voiding at volume thresholds, with the feeling of
urgency accompanying this smooth muscle activity. Micturition is allowed with voluntary
relaxation of the external urethral sphincter in concert with involuntary detrusor contraction
allowing urine to exit through the urethra. While some residual volume may remain, only
volumes greater than 50 ml are indicative of possible voiding dysfunction[22].
The cross-sectional anatomy of the urinary bladder is pictured in Figure 2. Tissue
in the interior of the bladder is protected from the toxicity of urine due to a mucosal
membrane barrier of glycosaminoglycan atop the superficial layer of umbrella cells. These
5

Fig 2. Diagram of Bladder Wall Cross Section. Adaptable umbrella cells atop underlying layers are
protected from bladder contents by a glycosaminoglycan layer (GAG)[3].

cells are capable of compacting into inverted umbrella shapes when the bladder is empty
and becoming more squamous during filling and distention[23]. Umbrella cells form tight
junctions with one another, establishing a regulated impermeable layer between the
underlying tissue and bladder contents while resisting mechanical stress with expansion
and stretch of the urothelium. Beneath the upper layer of the stratified transitional
epithelium lies at least two additional cell layers: an intermediate layer of moderately sized
cells and a basal layer consisting of smaller cells that make contact with the lamina propria
separating the urothelium from the submucosa[24]. Sensory afferent innervation penetrates
the lamina propria and is found throughout the basal layer, possibly providing information
on bladder wall shear stretch indicating degree of distention. The vast majority of the
vascular network is found within the submucosa, providing oxygen, waste, and nutrient
exchange to the adjacent urothelium and detrusor muscle. This network of arterioles and
capillary beds contains unique adaptions that allow blood vessels to coil within elastic
6

``sheaths in an empty state and uncoil during filling to provide consistent blood supply
until intravesical pressure finally extends these coils their full length (Figure 3). This leads
to stretching and a decrease in vessel diameter and perfusion[25]. Outside the submucosa,
the detrusor muscle is composed of primarily parasympathetic innervated smooth muscle
cells. The detrusor is the driver of micturition and amplifies feelings of urgency with
involuntary contractions increasing intravesical pressure[26]. The outmost layer of the
bladder wall is the adventitia, a serous membrane populated by larger blood vessels that
divide into the submucosal network.
In simplest terms, the bladder has been described as an elastic hollow organ that
passively fills and empties with some active assistance from smooth muscle contraction
[27]. This description oversimplifies the vital role the bladder serves and fails to convey
the uniqueness of its adaptions. While there are other hollow organs that employ similar
transitional epithelium tissue to allow for distention (e.g., the gastrointestinal tract), these
organs do not undergo the enormous swings in volume content and prolonged expansion
and contraction that the bladder must endure every day. The steady filling of urine (from

Fig 3. Corrosion Casting of Capillary Network of Dog Bladder. Multiple branching capillaries
provide extensive tissue coverage with numerous interconnected vessels[5].
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less than 50 ml to 500 ml or more) and subsequent voiding in a matter of hours – often
multiple times a day – means the bladder must change its shape drastically and quickly in
a frequent cyclic nature.
Positive intravesical pressure produces significant strain on tissue integrity and
perfusion that would be damaging in most tissues. However, the bladder employs various
mechanisms and redundancies that mitigate these stressors. Vesicular arteries within the
basal layer the bladder are encased in a tubular sheath composed of elastic fibers and
connective tissue within which the arteries may coil to reduce pressure on the vessels[25].
These structures may additionally serve to maintain arterial position in the face of constant
flux in bladder wall surface area. No other organs have been observed to utilize this
adaption for their blood supply[25]. Other distinguishing characteristics include: extensive
anastomoses providing multiple avenues of blood flow between arterial and venous
components; abundance of venous valves and arterial sphincters to reduce resistance to
flow; and independence between mucosal and submucosal vascular beds allowing for
distinct movement of each during distention[5]. On top of these physical adaptions are
cellular mechanisms to counteract the possible adverse effects of the vascular myogenic
response – all in service to maintain bladder tissue perfusion in the face of a transiently
ischemic environment.
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Overactive Bladder: The Scope of the Pathology
The clinical diagnosis of OAB is defined by “urinary urgency, usually accompanied
by frequency and nocturia, with or without urge incontinence, in the absence of a urinary
tract infection (UTI) or other obvious pathology”[28]. However, the definition can be
difficult to apply to patient reports because symptoms such as urgency are difficult to
characterize and quantify. As such, many studies become reliant on urinary frequency as a
measure of OAB progression. This too can be influenced by multiple factors including
fluid intake, use of medications, amount of sleep, etc. Thus, the definition of OAB requires
health care practitioners in charge of diagnosis to follow a procedural elimination of
explanations for increased urinary activity before determination that the presentation is
likely due to OAB alone. Quantifying the rate of OAB occurrence in the general population
is

complicated

by

multiple

factors

as

well.

First

is

the

potential

for

underdiagnosis/misdiagnosis in patients with comorbidities. For example, individuals with
diabetes that report increased urination can have their symptoms attributed to the classical
presentation of polyuria due to the metabolic disorder and be overlooked as a possible
sufferer of OAB[8]. Similarly, reports of urgency and incontinence from elderly
individuals can be perceived by many health care workers as simply an expected outcome
of the aging process and choose not to treat it[29]. The reverse can be the case as well,
where OAB is mis-diagnosed due to similar symptoms being created by a separate disease
process like diabetes or behavioral activities of the patient, such as excessive fluid
consumption. Due to the misdiagnosis and underdiagnosis of OAB in patients with
comorbidities, many recent studies attempt to exclude individuals with diseases known to
mimic OAB[30]. Studies observing differences between men and women have shown
9

women are not more likely to experience urgency than males; however, their presentation
typically includes slightly higher incidence of urinary incontinence[8]. Further
complicating the likelihood of OAB diagnosis is that patients are often not forthcoming
with information about symptoms they are experiencing due to the sensitive nature of the
problem and associated social taboos.
Among children there is a 5-12% prevalence of OAB between the ages of 5-10
years which sharply drops to less than a percent in older adolescents[31]. About a third of
children with OAB develop OAB later in their adult lives[31]. However, this may in fact
be the result of coping mechanisms created in adolescence now failing to compensate and
thus creating a reappearance of symptoms actually representative of chronic OAB[32].
This challenges a common assumption that juvenile OAB was simply something to
“outgrow” and may in fact indicate that the prevalence of chronic OAB in adolescence and
young adulthood is higher than for which studies can account. Despite these challenges, a
pattern of steadily increasing incidence of OAB with age has been established with a mean
prevalence of approximately 16% for both men and women across all age groups in the
United States[8]. With a population of over 325 million, the USA must contend with the
economic burden and cultural impact of over 50 million affected individuals.
A consistent trend in sufferers of OAB is generally lower physical functioning,
mental health, and quality of sleep as determined by standardized and validated quality of
life scales[8]. This is true even after adjusting for individuals with comorbidities or use of
medications that cause symptoms similar to OAB. With the prevalence of OAB becoming
more acknowledged in recent years, the economic burden of managing its effects has
10

become more apparent. In 2007, an estimate placed the US at a loss of $66 billion in costs
due to managing this disease, including diagnosis and treatment costs, incontinence pads,
and expenses due to comorbid conditions[9]. This estimate also included indirect costs,
such as lost wages and productivity from both patients and caregivers alike, as well as the
intangible costs of disruption and suffering for the patient and family. The daily hardships
of affected individuals coupled with the expense of addressing the disease ensures that
finding a cost-effective treatment holds enormous potential for researchers and drug
development companies.
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Current Treatment Options
For the many individuals burdened with the daily inconveniences of OAB,
mitigation of symptoms can become a high priority to maintain a desirable and fulfilling
lifestyle. It is unfortunate that the usual progression of ineffective behavioral modification
followed by poorly tolerated medications is the common path of treatment for most
patients. All various treatment options (antimuscarinics, β3 adrenergic agonists,
onabotulinumtoxin injections, and surgical device implantation) operate on the strategy of
directly relaxing the bladder wall often with significant adverse effects, surgical risks,
and/or monetary expense to individuals[33]. While these options can be efficacious in some
patients, this approach grossly oversimplifies the solution by treating the downstream
symptoms without examining possible upstream targets that more directly address the
problem.[33].
Initial treatment with BSC (consisting of behavioral modification, diet and fluid
reduction, weight loss, incontinence pads, and ad hoc urethral catheterization) costs
approximately $1,100 per year, but only 20-30% of patients experience complete remission
from this approach alone[10, 12]. Nonetheless, this treatment remains a baseline therapy
throughout management of OAB. Most patients are encouraged to seek pharmacotherapy
if BSC alone does not result in significant improvement (50% reduction in urinary
incontinence events)[10, 30]. Subsequent therapies are also assessed on their ability to meet
this threshold demonstrating superior efficacy. Antimuscarinics are the typical follow-up
to BSC. These drugs work by blocking activation of postganglionic muscarinic receptors
by

its

endogenous

neurotransmitter

acetylcholine
12

(ACh),

thereby

preventing

parasympathetic activation of contraction in the smooth muscle of the bladder[12]. While
some patients respond positively, these medications are associated with multiple common
adverse events that also negatively impact a patient’s quality of life. Muscarinic antagonists
such as oxybutynin and tolterodine induce urinary retention, dry mouth, constipation, and
central nervous system impacts such as somnolence[12]. These side effects, especially if
coupled with poor efficacy in some cases, have led to a high level of discontinuation (431%) even in a relatively short 12-week clinical trial[12]. This indicates that many patients,
having attempted antimuscarinic therapy, would: (1) prefer to live with the disease than
tolerate the side effects of the medication; or (2) were unable or unwilling to explore
additional treatment options. Additional study has also implicated anticholinergics,
including these urological antimuscarinics, as drivers of increased risk for developing and
worsening dementia in the long-term on top of the known short-term cognitive decline
associated with these medications[34]. While subsequent therapies have demonstrated
similar efficacy over antimuscarinics and often with higher patient compliance, the cost of
these therapies can be too high for many sufferers of OAB to justify. Thus, the patient and
their physician must then weigh the potential for adverse events associated with medical
treatment and other interventions as well as the cost of each treatment for OAB, while
determining if there is truly any benefit in health-related quality of life.
A cost effectiveness study conducted in 2019 illustrated varying degrees in health
states in OAB over a 10-year period[10]. The progression of health states, determined by
daily number of urinary incontinence episodes in 3-month cycles, was observed in
candidates receiving specific treatments. Changes in these health states across 10 years
were then mapped, with each health state assigned a value representing costs of disease
13

management reflective of clinical practice. Costs of treatment options were compared to
BSC as a reference therapy (and the lowest cost option) at about $1,150 a year. Patients
could expect a small incremental increase between $130 and $190 a year with
anticholinergics such as tolterodine and solifenacin over BSC. The cost of mirabegron, a
β3 agonist that demonstrated similar efficacy to antimuscarinics with more tolerable side
effects[35], can be estimated around $330 a year over BSC. Non-pharmacological therapies
include percutaneous tibial nerve stimulation (PTNS) at $260 extra a year and surgical
intervention with sacral nerve stimulation (SNS) implant at an additional $1,640 a year.
These peripheral nervous system-based therapies have demonstrated increased efficacy
over both antimuscarinics and mirabegron[10]. However, SNS comes with significant
surgical risks and high cost while PTNS requires weekly treatment sessions over 3 months
that can be inconvenient to many patients. Finally, botulism toxin intramuscular injections
(at $360 yearly over BSC) have shown the most dramatic improvement in efficacy over
baseline and first-line pharmacotherapy and is the most cost effective in the event of
inadequate response to BSC alone[10]. Peak onset of action is not expected for 2-6 weeks
after initiating regular injection appointments with the predominant side effect of local
muscle weakness at the site of the injection, but minimal systemic adverse effects
compared with antimuscarinics. Patients that experience initial relief of symptoms may
tolerate the inconvenience and risk in the short term. With continued use, there is a longterm discontinuation of Botox therapy with two-thirds of patient returning to classical
pharmacotherapy management within 3 years[36]. On top of this, the risk of adverse events
is relatively high with 16.8% incidence of urinary tract infection, 22.6% requiring
intermittent self-catheterization, and 22.6% incidence of post residual volume (>150 ml
14

indicative of urinary retention) within the first 3 years of treatment. Uniformity in treatment
protocol among urologists also remains an obstacle to consistent symptom relief with some
procedures using intradetrusor or suburothelial injections and the number of injection sites
ranging between 20-30 points[37, 38].
While there have been advancements in increasing the efficacy of therapies
targeting bladder muscle contraction while limiting severity of side effects, the patient and
caregivers still face an uphill battle of only being able to manage symptoms of OAB
without addressing the root cause. Further understanding of the onset of OAB is required
to elucidate additional targets for therapies that may prove more efficacious with less strain
on the patient in terms of cost, adverse effects, and convenience.
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Myogenic Tone & The Maintenance of Blood Flow
In most tissues, blood flow is maintained consistently despite fluctuating central
arterial pressures[39]. This is important given that unregulated intraluminal pressure can
destroy small arterioles and capillaries and disrupt perfusion to the surrounding area. To
prevent obliteration from sheer stress caused by pressure-dependent increases in volume
and blood flow, most arterioles constrict in response to increased luminal pressures
independent from nerve input[40]. Small vessels will also relax during periods of decreased
arterial pressures, thus decreasing peripheral vascular resistance and maintaining flow and
perfusion pressure[40]. These intrinsic properties, known as “pressure-induced
constriction” or “myogenic tone”, have been clearly identified in blood vessels from a
multitude of vascular beds including splanchnic, renal, and cerebral circulations[41-43].
These organ systems, being highly susceptible to ischemic injury, require these
mechanisms to perform their biological functions while maintaining constant tissue
perfusion. The kidneys, for instance, receive 20% of cardiac output and are responsible for
filtration of bodily waste and regulation of water and salt content. Functional glomerular
filtration rate (GFR) is dependent on blood flow, which is maintained by myogenic
mechanisms and tubuloglomerular feedback in response to upstream pressures[43]. In the
absence of myogenic tone, increases in upstream blood pressure transmitted to the kidney
result in a GFR that is too high and would overwhelm the absorptive abilities of salt and
water from the renal tubules and cause substantial structural damage to the glomeruli[43].
Likewise, decreased arterial pressures would decrease GFR to the point where metabolic
waste and other solutes would not be adequately filtered and remain in circulation if
myogenic tone be absent. Myogenic tone of efferent and afferent renal arterioles thus
16

maintains normal GFR by responding locally to contract or relax vascular smooth muscle.
Other small vessels preserve normal functions in other areas of the body in similar manner.
While myogenic activity has been identified for over a hundred years and demonstrated
throughout the body, understanding the details of the cellular mechanisms responsible for
it is an ongoing process. Specifically, the correlation between pressure increase within the
vessels and subsequent membrane depolarization is an area of active research and debate
within the scientific community. The initial detection of muscle cell stretch with increasing
intraluminal pressure may involve a number of candidates, including stretch sensitive ion
channels and volume-regulated chloride channels[42, 44]. There is consensus that opening
of voltage-dependent L-type calcium channels from the initial depolarization results in
contraction of the vascular smooth muscle and constricting vessel diameter[45].
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Inward-Rectifier Potassium Channels in Bladder Arterioles
Inward-rectifier potassium channels provide important control of cellular
membrane excitability in numerous tissues, such as the kidneys, heart, and brain [46].
These channels can be characterized by the mechanisms that govern their opening and
closing and how they behave in a changing mechanical, electrical, and chemical
environment. Inward-rectifier potassium channels (KIR channels) are a family of ion
channel proteins that range from approximately 360-500 amino acids in length. Individual
subunits consists of two membrane-spanning helices sandwiching a long pore region of
negative amino acids which facilitate ion-selective flux and an intracellular amino and
carboxy terminus[46]. A complete channel is a tetramer. These channels are “inwardly
rectifying” in that, as a function of
membrane

potential,

they

demonstrate a large inward current at
negative potentials and very little
outward current at positive potentials
(Figure 5)[47]. This is predominantly
due to cytoplasmic polyamines or
Mg2+ that plug the pore at positive
membrane
Fig 4. Inward-Rectifying Channels Prevent Outward
Current at Positive Voltages by Closing the Channel. A
simplified graphic contrasts the inward rectifying
signature with an always open cation channel which
produces a near linear relationship[4].

potentials[47].

The

presence of these channels allows for
membrane potentials to align closer
with

potassium’s

equilibrium

potential in most cases, ensuring a more hyperpolarized membrane potential[48].
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Interestingly, these channels are activated with increasing extracellular potassium resulting
in steadily increasing potassium permeability, thus coupling membrane potential to the
equilibrium potential for K+[49]. Much higher concentrations of extracellular potassium
(60mM, EK=-22mV) however tips the balance towards depolarization, positive membrane
potentials, and inactivation of the KIR channels[45].
The KIR2 subfamily are characterized as “strong” inward rectifiers, meaning the
lack of outward current is more pronounced at positive voltages and are less likely to have
positive current at positive membrane potentials than weak inward rectifiers[48]. KIR2.1 is
found systemically in the body within smooth muscle and is shown to mediate resting
membrane potentials within the vascular smooth muscle with evidence of increased
potassium inward currents with increased sheer stress[50]. This activity is suspected to
maintain a counterbalance to a tonal response to shear stress by amplifying endothelium
mediated vasodilatory activity[51].
Vascular
smooth muscle tone is
tightly controlled by
the

endothelium,

which

responds

to

chemical and physical
Fig 5. Inward-Rectifier Subtypes. Inward-rectifiers display
predominantly inward current but will have some outward current as
potential becomes positive before it closes. How fast a channel
“corrects” the outward current distinguishes strong inward-rectifiers like
KIR2 family from weak ones such like KIR3 subtypes[7].

19

signals to modulate
vessel

diameter

relaxation

of

the

underlying smooth muscle. These two layers are connected electrically through gap
junctions at myoendothelial projections with membrane potential hyperpolarization
resulting in deactivation of L-type voltage-dependent Ca2+ channels allowing muscle
relaxation and vasodilation[52]. One of the primary vasodilatory pathways involves
establishing this hyperpolarized state through Ca2+ signaling via transient receptor potential
vanilloid 4 (TRPV4) channels within endothelial cell membranes and inositol triphosphate
receptors (IP3R) within the endoplasmic reticulum[53]. These calcium signals then
activate small and intermediate conductance (SK & IK) channels that drive efflux of K+
immediately adjacent to the vascular smooth muscle cells and transmit the accompanying
hyperpolarization to the smooth muscle as well. This increase in local K+ concentration
activates strong inward-rectifier potassium channels in the smooth muscle cells to amplify
the hyperpolarization and ensure a stronger vasodilatory activity.
A study conducted by Tykocki et al. illustrated that isolated bladder feed
arterioles did not develop myogenic tone pressures (Figure 4) but were shown to still
have healthy smooth muscle activity with application of vasoconstricting agents such as
phenylephrine and KCl[1]. It was also shown that the lack of a pressure-induced
constricting response was not due to an overwhelming influence from the endotheliumderived dilator nitric oxide, as inhibition of nitric oxide synthase did not affect vascular
diameter. Smooth muscle cell membrane potential was hyperpolarized at rest, suggesting
the underlying mechanisms responsible for initiating myogenic tone have a higher
threshold to initiate depolarization. Smooth muscle cells displayed Ba2+-sensitive K+
currents, implying the observed hyperpolarization was likely due to strong inwardrectifier K+ channels. Finally, smooth muscle-specific knockout of KIR2.1 resulted in
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myogenic tone within the bladder arterioles consistent with other tissues. With KIR2.1 as
a primary hyperpolarizing influence in bladder vascular beds, the working theory is that
KIR2.1is responsible for maintaining hyperpolarization of the vascular smooth muscle cell
membrane potential such that the myogenic depolarization mechanisms are unable to
overcome it in the face of increasing intraluminal pressure[1]. This suggests that
suppression of the myogenic response is a physiological standard within the bladder, not
an exception. Understanding that the main objective of the vasculature in any organ
system is to prevent ischemia, we can surmise that the absence of myogenic tone in the
bladder helps preserve perfusion as the bladder undergoes constant changes in shape and
increasing physical stressors.

Fig 6. Vascular Response in Bladder Arterioles. “Failure” to initiate myogenic response with
increasing intraluminal pressure in bladder arterioles vs inhibition or knockout of KIR2.1
resulting in “restored” myogenic tone in the bladder[1].
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Hypothesis
Previous work has illustrated that, while most vascular beds in tissues throughout
the body exhibit myogenic tone, the bladder vasculature displays passive responses to
changes in intraluminal pressure[1]. It is theorized that this is a physiological adaption that
prevents tissue ischemia in the context of the stretch and pressure applied to the vasculature
during bladder distention. It has also been demonstrated that acute ischemia results in
increased detrusor contractility and bladder overactivity that eventually progresses to
underactivity if flow is not restored[19]. It has not yet been shown that the pathological
presence of myogenic tone in the bladder results in symptoms of OAB, or that changes in
vascular tone alone can cause OAB.
The objective of this project is to determine if the development of myogenic tone
in bladder arterioles is capable of causing an increase in urination frequency in mice,
thereby showing that changes in vascular tone likely induces ischemic conditions rapidly
that precipitate symptoms of OAB. We hypothesize that the myogenic tone that develops
in bladder arterioles after the genetic deletion of KIR2.1 channels results in a chronic
ischemic bladder resulting in symptoms of OAB, which is represented in increased
urination frequency and decreased voiding volumes in smooth muscle-specific KIR2.1
channel knockout mice.
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Historical Practices of Measuring Voiding Activity in Mice
One of the greatest challenges of modeling bladder pathologies in mice requires
acknowledging the disparities between murine and human physiology and behavior. For
one, mice have a basal metabolic rate per gram of body weight seven times that of
humans[54]. As such, mice are consuming and excreting at a rate that far outstrips humans
– meaning the rate of urine production is far from perfectly representative of a human renal
system. Additionally, the limited murine urinary bladder capacity ensures void frequency
is significantly higher than in humans with most void volumes ranging between 100-300
µl with up to 10 micturition events in a 24 hour period[55]. On top of this, mice do not
have the social and cultural constraints governing their voiding behavior as humans do
allowing for their elimination to be solely dependent on their consumption and physiologic
status. All of this illustrates that modeling OAB in mice requires establishing a baseline of
normal behavior that accounts for factors including age, fluid intake, and environment
while understanding that changes in voiding behavior is multifactorial and not a direct
comparison of human physiology and pathology.
Another challenge is determining precise and accurate methods of measuring
voiding activity in conscious mice while minimizing as many stressors as possible. While
cytometry has been a gold standard in determining bladder capacity in both conscious and
anesthetized mice[56], these experiments require catheterization through the dome of the
bladder wall that circumvents the normal direction of urine while causing tissue damage in
the process. There is also the fact that filling and voiding rates and volumes are entirely
researcher controlled and usually supraphysiological. Finally, OAB cannot be modeled in
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subjects under anesthesia given the behavioral component of the syndrome and the
interference of inhaled anesthesia with the micturition reflex in mice[57]. This requires a
thorough experimental design that accounts for: (1) mice are social animals that normally
live in small groups[58] and as such sustained isolation is likely to result in altered
behavior; (2) it is necessary to segregate mice for a period of time to ensure collected urine
belongs to the mouse in question; (3) the apparatus for measuring micturition must be
reasonably accurate and precise while isolating feces and other confounding factors (food
droppings, ambient air disturbances) from voiding events; and (4) the experimental setup
and procedure should minimize stress on the mouse to prevent deviation from normal
behavior, as stress alone alters murine voiding behavior[59].
Fairly recent studies seeking to provide reliable means of quantifying micturition
behavior in mice have utilized the “void spot assay”[60]. This procedure placed mice in
clear cages in proximity with other mice while being isolated with a wire-netted floor
suspended 20cm above a filter paper. These mice were hydrated and fed prior to the
experiment but were not allowed food or water for the 2-hour duration of the experiment.
As urine and feces would drop through the cage floor onto the filter paper the urine would
create blots on the paper that would be visible under UV light when dry. Void volume
could then be extrapolated from the blot surface area respective to standards established by
blotting filter paper with known volumes of normal saline or urine. While this method is
effective in isolating urine from contaminants this approach suffers from several
drawbacks. First, the experiment did little to address comfort for the mice, lacking
enrichment devices, social interaction, food, and water that would all serve to ensure the
mice were behaving as close to how they would behave in storage within animal facilities.
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This experiment was also conducted in a limited time frame thus limiting time for mice to
habituate to their surroundings and possibly effecting behavior. Finally, extrapolating data
from the void patterns is far from foolproof given that one or more voiding events could
happen on top of an existing urine blot – effectively limiting what events could become
part of the data set. While this setup has some advantage over metabolic cages which will
be discussed next, the void spot assay certainly has room for improvement.
The metabolic cage system has been in use for decades in nutritional studies, drug
excretion experiments, renal function studies, and numerous other research designs with
rats and mice where the separation and collection of urine from feces was essential[61]. A
transparent polycarbonate enclosure with a steel rod floor could provide enough space for
the addition of enrichment devices along with modular food and water hoppers are
designed to minimize stress on the animal while allowing for extended data collection
upwards of 24 to 48 hours. These data, being a direct measurement of urine excretion as
opposed to derived from void spot diameters from paper blots, is more easily quantifiable
and urine samples could be more readily obtained for further analysis. The construction of
the collection apparatus allowed urine and feces to separate into distinct collection tubes
where they could be easily removed with minimal disturbance to the mouse. However, the
detection of individual voiding events and volumes is not possible in most commercial
units due to the design of the collection system prioritizing the separation and consolidation
of waste for further analysis. Another significant limitation in obtaining accurate
measurements from metabolic cages is due to loss of volume during capture from
adherence to the collection system and failing to reach the measuring vessel. These systems
work well in larger rodents, but struggle to record voiding in mice. Furthermore, the
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importance of minimizing animal stress to ensure relevant experimental results have been
emphasized[62] with recent studies demonstrating mice do not habituate to their temporary
surroundings in metabolic cages even across several hours[63]. Future experimental
designs seeking to improve the resolution of the data must make animal comfort a priority
as much if not more so than the design of the measuring instrument.
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The UroVoid System: Increasing Accuracy in Measuring Mouse Voiding Behavior
The UroVoid system (Figure 7) sought to combine the advantages of the void spot
assay and the metabolic cage while mitigating both of their disadvantages. Objectives in
the design of the cage system were to obtain high resolution measurements of individual
voiding events in conscious mice while preventing contamination from non-urine
droppings – all while ensuring the living space minimized animal stress. Like a metabolic
cage, the UroVoid suspends the animal over the mechanical separation system via a steel

Fig 7. The UroVoid System. The UroVoid houses mice over a grid-rod floor, allowing feces and
urine to fall below. A screen separates solid waste from urine, which falls onto the scale recording
fluid mass, time, and duration of void. Food and water receptacles are sufficiently isolated from
the cage without denying animal access. Enclosure of the scale prevents air current artifacts.

rod floor with space for the animal to move about between access to food, water, and shelter
(autoclavable enrichment huts). Contamination from food and water is prevented via the
modular design of the hoppers, which contain spilling within the unit while being small
enough to discourage the animal from sheltering within them. The filtration mechanism is
differentiated from metabolic cages by using a fine mesh grid instead of a tube system that
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captures solid droppings and allowing urine to pass through. The urine lands on a pan
resting on an analytical scale, thus minimizing fluid loss due to surface adhesion. Time
stamped mass measurements are then transcribed to the proprietary software to provide
uninterrupted data of void volumes across 24-48 hours and potentially longer (Figure 8).
The UroVoid design seeks to effectively eclipse the measuring efficacy of previous
concious voiding experiment protocols while maintaining the benefit of utilizing a noninvasive method verses cystometry. This allows for multiple trials at near-physiologic
conditions in a single animal that can be paired with subsequent tissue analysis as the
bladder is not disturbed surgically.

Fig 8. Representative Micturition Trace of a C57 bl/6j Mouse at 12 Weeks Old over 48 hours. Trace
depicts a typical microgram of an unaltered adult mouse with voiding events marked with red circles
and characterized by evaporation curves following the peak.
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Cre-loxP System for Inducible Knockout of Target Genes
Use of pharmacologic agents to promote or inhibit subcellular targets as a means
of representing a disease state is problematic given that these targets are often systemic.
Observing the effects in a single organ system in vivo while inhibiting an ion channel
systemically would undobtedly result in multisystem pathophysiological developments
confounding observations and potentially killing the animal. Genetic manipulation allows
for a much more specific approach to model a pathology, though some offer a more focused
approach than others. Germline manipulation of genes to represent disease states in mouse
models carries with it disadvantages that make the inducible knockout system highly
preferable. Most notably, the deletion of various genes may prove terminal or produce
sever afflictions during early development[64]. Therefore, the use of inducible genetic
knockout through the Cre recombinase-loxP mechanism provides researchers with the
means of deleting a gene of interest when desired without affecting normal development.
Targeting a gene for deletion with the inducable kockout method involves altering
the genome of one mouse strain to flank the gene of interest between two identical loxP
sites[6](Figure 9). The region of sandwiched DNA is now considered a “floxed” gene that
can be excised in the presence of active Cre recombinase. Cre recombinase recognizes the
two repeating loxP sites and produces an inactive circular segment of the floxed gene. DNA
repair mechanisms then repair the break, removing the loop and allowing transcription to
occur again without the expression of the floxed gene. Breeding between floxed strains and
mice that constitutively express Cre recombinase produces offspring with a knocked out
gene. To ensure Cre recombinase expression is tissue specific, the Cre gene is often
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downstream of a signature promotor of the tissue or cell type being targeted. Furthermore,
to give temporal control over the expression of Cre, the Cre protein is fused with an
estrogen receptor that contains a ligand binding domain for the estrogen receptor modulator
tamoxifen. In the absence of tamoxifen, the Cre enzyme is located in the cytoplasm and
bound to its inactive cytoplasmic ligand, heat shock protein 90 (HSP90)[6]. The Cre
remains inactive until tamoxifen administered by the researchers displaces HSP90 allowing
the complex to return to the nucleus and act on the loxP sites. In our project, this mechanism
provides the means for the selective removal of KIR2.1 channels from the vascular smooth
muscle in the bladder specifically at a time of our choosing.

Fig 9. Cre Recombinase-loxP Mechanism. Prior to drug administration the knockout mouse Cre
recombinase is rendered inactive due to translocation to the cytoplasm preventing its interaction
with loxP sites. The enzyme is made active and returned to the nucleus in the presence of
tamoxifen which displaces its cytosolic ligand on the estrogen receptor subsequently deleting the
floxed gene from the sequence[6].
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Tamoxifen Dose-Response
On its surface, the Cre-loxP inducible knockout system is versatile and selective,
but previous work has also demonstrated it is robust as well. It must be shown that a
reasonable dose of tamoxifen can activate Cre recombinase sufficiently to scale in
hybridized mice. The tissue-specific disruption in a time-dependent manner was achieved
by researchers observing relative mRNA expression of Serca2, a gene belonging to a
family of P-type cation pumps within the endoplasmic reticulum, within cardiac
myocytes of transgenic KO mice[2]. In this study, researchers demonstrated over 90% Credependent disruption of Serca2 in the mouse myocardium within 4 days of initiating
treatment and at lower tamoxifen dose (80mg/kg vs. 100-800mg/kg) than in prior studies
using the Cre-loxP system of inducible knockout. In addition, the researchers showed

Fig 10. Comparison of Tamoxifen Dose for Effective Gene Knock Out. Mice receiving greater
dosages of tamoxifen exhibit diminishing incidence of Serca2 gene KO with 2x, 3x, & 5x dosage
groups statistically equivalent of one another (one dose is 1mg/day/mouse i.p. injection). The
right-hand graph maps the efficacy of gene KO over time and compares i.p. injections with
tamoxifen feed delivery. By 4 days after first treatment in any tamoxifen receiving group
regardless of method the mRNA gene signature of the floxed gene is less than 10% of baseline
abundance[2].
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similar KO efficacy between intraperitoneal injections and non-pellet feed for tamoxifen
delivery. These results indicate a rapid response of the Cre-loxP system can be expected
through multiple methods of tamoxifen administration at reasonable dosages.
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Animal Care & Use
Smooth muscle cell-specific potassium inward rectifier knockout (KIR2.1SMKO) mice
were prepared via cross between floxed KIR2.1 (Kcnj2) mice and mice expressing
tamoxifen-inducible Cre recombinase (CreER(T2)) under the myosin heavy polypeptide
11 smooth muscle (Myh11) promotor (SMMHC-CreERT2; courtesy of Dr. Stefan
Offermanns). These cross-bred mice were first observed in the UroVoid® system (Med
Associates, USA) at approximately 4 weeks of age for voiding activity prior to treatment.
At 6 weeks old mice were either surgically implanted with a time-release tamoxifen pellet
(10 mg/kg total over 2 weeks) or sham surgery. A separate cohort of mice underwent oral
gavage treatment (see below for dosing). Mice were then evaluated for voiding activity
again at 8 and 12 weeks in the UroVoid system.
Tamoxifen Citrate Pellet Implantation

KIR2.1SMKO mice were anesthetized with isoflurane. The area just behind the shoulders
were clipped and prepped with betadine. Tamoxifen citrate extended-release pellets (5 mg
total, 21-day release; ~2 mm diameter) were implanted subcutaneously using a 10-gauge
trocar. Trocar wounds were closed using a wound clip or sterile suture. In the event of
complication with implantation using the trocar method, a small incision was made with
sterile scissors and a small sub-cutaneous pocket was bluntly dissected. Pellets were then
implanted in the pocket and closed with sterile suture.

Prior to recovery from anesthesia, mice received one subcutaneous dose of buprenorphine
for analgesia (0.05-0.1 mg/kg body weight). Mice were observed on a daily basis for
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potential development of swelling at the implant site. If observed, mice receive
buprenorphine for analgesia (0.05-0.1 mg/kg body weight) subcutaneously every 12 hours.
If swelling did not abate within 72 hours, mice would be euthanized. Through all
experiments, no mice received more than the initial dose of buprenorphine nor were any
euthanized due to complications of surgery.

Liquid Bolus Tamoxifen Oral Gavage

Tamoxifen purchased from Sigma-Aldrich (T-5648); was used to make stock at 50 mg/ml
in corn oil (Sigma Aldrich C-8267). Tamoxifen solution (0.2mg/g of mice) was freshly
prepared before each round of oral administrations, kept at 4°C, and warmed before use.
Drug or vehicle was administered once daily by gavage for 5 consecutive days.
UroVoid Experimental Procedure
The weight of both the mouse and water reservoir were determined prior to placement of
the subjects in the UroVoid. Mice were provided ample ground dry chow in addition to
their water reservoir and a living enrichment object (mouse hut) with the structure of the
apparatus ensuring the inferior body of the mouse was always present over the cage floor.
Subjects were kept for 48 hours with minimal interruption in a controlled lighting (12/12
on/off), humidity (60%), and temperature (21° C) environment. Subjects were inspected
and food hoppers were refiled approximately 24 hours into the experiment with times
noted. At the conclusion of each experiment, mice and water reservoirs were weighed again
and trace data were visualized using UroVoid Analysis® software.
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UroVoid Measurement Validation
Four UroVoid machines were tested simultaneously for measurement accuracy. Traces
were obtained for varying fluid (Millipore water) volumes dropped on the scale with
multiple setups to test interference of the grid rod cage floor and the solid-waste filter
screen. Fluid volumes (5, 10, 20, 50, 100, 200, 400, 600, 800, & 1000 µl) were dropped
from an approximate height of 2 cm from the cage floor in all four corners and the center
of the floor, five times in each location for a total of 25 volumes administered per scale per
experiment. Average fluid volumes in each condition, (no screen or cage, screen present
without cage, cage present without screen, complete setup), were determined and compared
with one another to observe for loss of fluid due to liquid adhesion to different parts of the
apparatus. When the screen and grid rod cage floor was present, samples were purposefully
dropped in a way that contacted both the floor and screen to re-create a “worst-case
scenario” where mice voided directly over a grid rod.
Additionally, powdered food formula was dropped from similar height through the cage
floor and filter screen to observe for trace patters of food particles not segregated by the
apparatus.
Single Cell RT-qPCR
Individual detrusor smooth muscle cells were isolated from bladder wall tissue samples via
digestion with collagenase (Type F; 1 mg/ml) for 20 minutes at 37°C, followed by manual
retrieval of roughly 10 smooth muscle cells using a hydraulic micrometer and syringe
pipette. Smooth muscle cells were identified by their fusiform shape. Cell lysis, reverse
transcription, and cDNA pre-amplification were performed according to the Single Cell35

to-CTTM kit purchased from ThermoFisher Scientific. Cell lysis began with 10 cells
incubated for 5 minutes at 25°C with 10 µL Single Cell Lysis/Dnase I solution. 1 µL Stop
Solution was added followed by a 2-minute incubation at 25°C before being stored at 20°C. Reverse transcription was performed with 4.5 µL RT Mix added and incubated for
10 minutes at 25°C, followed by incubation at 42°C for 60 minutes, then 80°C for 5
minutes. Subsequent workflow was performed by the University of Vermont Cancer
Center Cancer Translational Research Laboratory. Preamplification used 11 µL PreAmp
Mix/pooled TacMan assays (targeting Kcnq1-5, Kcnj2, Kcnj14 with Acta2 housekeeping
gene), added to the solution then held at 95°C for 10 minutes followed by 14 cycles of
95°C for 15 seconds and 60°C for 4 minutes. A 1:20 dilution was prepared prior to RTqPCR using 1X TE buffer (pH 8.0) prior to plating. cDNA was amplified first by holding
the samples at 50°C for 2min then 95°C for 10 minutes followed by 40 cycles of 95°C for
5 seconds then 60°C for 1 minute.
Statistical Methods
Statistical analyses were performed using GraphPad Prism (GraphPad Software, San
Diego, CA) or Microsoft Excel. Results are expressed as means ± SEM unless otherwise
specified. For comparison of multiple samples 2-way analysis of variance (ANOVA) with
Bonferroni’s multiple comparisons test was used (α=0.5). Two-tailed unpaired Student’s ttest (α=5) were used for comparisons between two groups. P values <0.05 were considered
statistically significant.
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Accuracy & Precision of the UroVoid System
As a new system for measuring urine output, the precision and accuracy of the
UroVoid’s ability to measure voiding events needed to be established. Liquid volumes
dropped from 2 cm above the cage floor were first measured with no interference with the
fluid trajectory (i.e., no cage or screen to interfere with droplets), or in a configuration with
maximum interference of fluid trajectory to the scale (i.e., liquid dropped directly on the
gridrods with screen in place). As expected, the scale shows high precision and accuracy
when measuring a specific volume (Figure 11) across the entire surface area when
interference with liquid is minimal. Providing interference from the filter screen and cage
floor increased the variance, while on average reducing mass measurements by
approximately 13.6 µl (6.78%) in the case of our 200 µl test. Larger volumes demonstrated
reduced percent fluid loss, which represents a smaller error and greater accuracy. However,
this lacks relevance when we consider that mice void volumes are rarely larger than 300 µl
in non-pathological conditions[55]. Volumes below 200 µL are notably more susceptible
to instrument error due to fluid adhesion when dripped directly onto the grid rod floor
(Figure 12). This poses a problem given the likelihood of small volume micturition events
when modeling OAB in mice. However, since the grid rods occupy less than 20% of the
total floor area, interference by the grid rod floor was less likely in true experimental
conditions.
When we investigate the resolution of the system at smaller volumes, the scale is
unable to accurately record actual mass at 20 µL and below (Figure 14). Some of this is to
be expected given the analysis parameters are configured to exclude minute disturbances
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to the scale to reduce noise. However, in doing so extremely small voiding events are more
likely to be missed thus instrumentally reducing the observed micturition activity.

Fig 11. Investigating Interference from Cage & Screen Examination of Fluid Loss from
Adhesion to the Cage Floor and Screen. Four Urovoid systems (Unit 1, 2, 3, & 4) are examined
by dropping 25 volumes of distilled water (200 µL or 100 µl each respectively) in five separate
locations of the scale tray (center and four corners). A. Scatter plot of scale measurements with
cage and screen in place (no interference from the cage floor or screen). B. We observe an
average decrease in the mean detected volume of 6.78% and an increase in variance of 0.061%
in the case of our 200 µl tests. These effects were not statistically significant.
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Fig 12. Precise Measurements Over a Range of Volumes. UroVoid consistency in measurement
of known fluid volumes with standard deviation. Results are shown as a percent of the known
volume pipetted into the UroVoid cage. N=4 cages with n=5 measures per volume.
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Fig 13. UroVoid Threshold Precision. Even without obstruction, 50 µl volumes dropped
directly onto the scale demonstrated significantly higher variance in measurements even in
similar locations (left side graph). Introducing maximum interference allows some events to
be missed thus measurements at 50µl and below are not reliable (not shown).
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20 µl

50 µl

Fig 14. Urovoid Event Attrition Configured Without Cage or Screen. 50 µl volumes are sufficiently
massive enough to register as events within the analysis parameters with no interference from the
cage floor across the entire surface area. 20 µl volumes and below are insufficient to register as
voiding events even without interference from the cage and screen with a mean rate of 81% failure
to register across four Urovoid systems.
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50 µl

100 µl

Fig 15. Urovoid Configured with Screen and Cage Floor for Maximum Interference Measuring
50 µl and 100 µl Volumes Respectively. Analysis parameters fail to register 25 events below 100
µl. A mean failure rate of 12% was observed across four Urovoid systems in 50 µl trials. Larger
volumes, 100 µl and above, consistently and predictably register as events without fail.
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Upon introducing interference using the complete setup with cage and screen in place, even
50 µL volumes begin to experience failure to register (Figure 15). Not all voiding activity
can be expected to experience maximum interference from the cage floor, but since there
is no means of determining when interference occurs it must be noted that void volumes
50 µL and below cannot be consistently measured and that error increases dramatically.
We can confidently claim that at 100 µL and above even with maximum interference there
is a 100% successful event registration. This is within the established normal void volumes
of mice according to prior studies[55]. However, prior studies utilized completely different
instruments and experimental design to determine “normal” mouse voiding volume. Unlike
prior studies, the UroVoid System offers the opportunity to observe micturition with high
temporal resolution over a substantially extended time frame. Concluding that the accuracy
and precision of the UroVoid System was such that mouse voiding could be measure with
reasonable consistency, we next collected experimental data from healthy mice for
comparison to reported voiding behavior using other methods.
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Using the UroVoid System to Measure Voiding Behavior in KIR2.1 Knockout Mice
Establishing analysis parameters ensures we collect the most quality data while
understanding the limitations of the UroVoid system assists us in interpreting the data.
Despite noting that mass measurements below 50µL that reach the scale risk event
registration failure it is still possible to collect a valid data point at these small volumes.
We want to strike a balance between collecting the most potential events and over
sensitizing the scale such that minute disturbances unrelated to voiding activity introduce
noise. Thus, we elected to use default parameters of 10 mg to trigger the start of a potential
voiding event with a 30 mg void threshold which would qualify an event when there is a
detected change of 30 mg on the scale within the time parameters. A trigger window of 1
second requires a possible event to exceed a 1 second duration of change in mass as
measured by the scale. This helps to catch some small void events that have a short
timeframe while removing mass measurements that would cause a near instantaneous
change in measured mass such as a fecal pellet bypassing the filter screen (i.e. likely not
flowing fluid). A long threshold window of 200 seconds would ensure long duration
voiding events could not be reported by the system as a series of overlapping smaller events
happening consecutively. Age-matched UroVoid trace data (mictograms) were collected
using these analysis parameters (Figure 16). These parameters mean most registered events
are likely fluid volumes dispensed over a period of time. Observing tell tail evaporation
curves following the event helps further exclude void measurements from solid matter
(fecal matter and food debris that escapes the hopper). However, this may not be sufficient
in distinguishing interference from water that escapes the reservoir hopper as the animal
drinks. Further direct observation of mice in the UroVoid would be required to determine
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the degree of interference from drinking water if at all. During our trials we could easily
observe if solid matter had breached the filter screen and visualize the time of the drop on
the trace data. Analysis parameters more often than not would exclude these points and if
there was registration a lack of an evaporation curve meant we could confidently remove
the data point.
Healthy unstressed mice have demonstrated typical voiding volumes above 100 µL
in prior studies[55, 65, 66]. As such we can expect accurate recordings should mice exhibit
this micturition activity. Stressed mice however have shown reduced bladder capacity in
cystometry experiments[59]. The UroVoid, despite efforts in its design to provide a
relatively comfortable living space, cannot fully replicate normal living conditions and may
introduce stress due to isolation of the animal and grid rod floor. Prior work has shown a
decrease in burrowing and nest building behaviors and body weight, indicators of distress,
when exposed to grid rod floors for 24 hours[67]. It is reasonable to expect increased
micturition due to stress from the UroVoid, possibly with volumes below 100 µL, as a
baseline requiring conservatively low threshold parameters even in control mice.
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KO

Sham

4 Weeks

8 Weeks

12 Weeks

Fig 16. Age-Matched Mictograms. Representative traces from a KIR2.1 knock out mouse at 4, 8,
and 12 weeks of age, respectively. Tamoxifen was given at 6 weeks of age, by either
subcutaneous pellet or oral gavage. Possible voids first must trigger the scale with a minimum
mass (10 mg) and exceed a void threshold (30 mg) within a minimum threshold window (200
seconds). Averages and SEM of Void mass, void number, and IMI are then calculated for
summary data.
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Relative Expression of Kir2.1 in Vascular vs. Detrusor Smooth Muscle
As described above, knockout of KIR2.1 channels from smooth muscle cells
resulted in the development of significant myogenic tone in bladder arterioles[1]. Thus, we
utilized the Urovoid System to determine if this also caused overactive bladder. Within
detrusor smooth muscle the KIR channel family is primarily represented by ATP-sensitive
K+ channels (KIR6)[68] although other KIR channels are broadly distributed including the
KIR2 family[69]. Since knockout of KIR2.1 occurred in all smooth muscle in our mouse
model, we first tested if detrusor smooth muscle expressed KIR2.1 channels under normal
conditions. Quantitative polymerase chain reaction (qPCR) was conducted to establish
relative expression of two inward rectifier potassium channel genes, Kcnj2 (KIR2.1) and
Kcnj14 (KIR2.4), in isolated detrusor smooth muscle cells (Figure 17). Relative expression
of Kcnj14 was significantly higher than that of Kcnj2 expression which was negligible
(unpaired student’s t-test, p=0.0101). Thus, knockout of KIR2.1 channels was likely only
altering contractility in smooth muscle of the vasculature rather than impacting the
governance of contractility in the detrusor. Prior work demonstrated successful knockout
of the target gene in vascular smooth muscle after tamoxifen treatment in KIR2.1SMKO
mice[1]. However, our current study did not utilize genetic testing as a control to ensure
mouse treatment groups were genotypically distinct and verify knockout of the Kncj2 gene.

47

✱

Fig 17. Prevalence of KIR2.1 in the Detrusor. Analysis of qPCR for markers of potassium
inward-rectifier channels in detrusor smooth muscle cells. Both Kcnj2 and Kcnj14 code
components of two KIR channels 2.1 and 2.4 respectively. Previous work has demonstrated
expression of these genes is not found to an appreciable quantity in the detrusor smooth muscle
and is distinctly expressed within the bladder wall adventitia.
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Urovoid Mouse Experiments
Floxed Kcnj2 (no Cre recombinase expression) mice were first assessed in the
UroVoid for change in phenotype in age-matched mice (Figure 18). Void volume and
intermicturition interval (IMI) unsurprisingly increased with age while there was no
appreciable difference between mice receiving tamoxifen (n=2) and sham treatments (n=2)
with respect to IMI at 12 weeks of age (unpaired student’s t-test, p=0.1199). Thus, we
cannot infer tamoxifen administration on its own is responsible for physiologic change in
micturition behavior.
As we transitioned to KIR2.1SMKO mice, we began initially with our surgical
protocol for control and tamoxifen receiving groups. Upon noting high variation in void
mass (Figure 19 B) and IMI (Figure 20 B) within treatment groups we elected to switch to
oral gavage drug delivery protocol surmising a less invasive procedure would be less
stressful on mice, provide an equivalent means of drug delivery, and reduce variation
within each treatment group. Oral gavage treatment groups saw more uniformity in their
void mass (Figure 19 A) and IMI measurements (Figure 20 A) even as the mice aged. Twoway analysis of variance (ANOVA) of IMI noted mouse age in gavage mice as having a
very significant effect on results (43.92% total variance, p=0.0084), while this was
considered not significant within surgery mice (16.71% total variance, p=0.0871). All other
factors including treatment and subject were considered not to have significant effect on
IMI or void mass.
Normal kidney function is an important control to establish prior to making
inferences about behavior. Any complication to GFR could skew the data to suggest
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bladder overactivity/underactivity when the pathology responsible is upstream. Urine
production rate (UPR) is a useful parameter in this regard when comparing mice. Since we
expect the inducible KO not to effect GFR while potentially altering bladder physiology
we anticipate UPR between sham and drug treated groups to be equivalent (Figure 22).
Additionally, UPR is a useful check on instrumental interference from fluid adhesion,
particularly in the case of very small void volumes. If the majority of void events are small
enough to be subject to significant error from volume loss, we would expect to see a
downward shift in UPR in these animals. Gavage mice exhibited typical progression of
increasing UPR with age (2-way ANOVA, 49.04% total variance, p=0.0007). In surgery
mice we did not observe this trend in age within the highly variable data (2-way ANOVA,
19.35% total variance, p=0.1420). With respect to treatment no significant impact on UPR
from tamoxifen was observed with both surgery (2-way ANOVA, 2.625% total variation,
p=0.4688) and gavage mice (2-way ANOVA, 0.2692% total variation, p=0.0.8533).
Maintaining a consistent day/night cycle of 12 hours of light and 12 hours of
darkness was one of our environmental controls. Mice are nocturnal animals and are most
active during the dark periods where we expect to see higher levels of micturition activity.
Number of voiding events for tamoxifen and control mice in both treatment protocols were
evaluated based on light (low activity/sleeping) and dark (active) conditions (Figure 22).
Time of day was considered extremely significant on void frequency in both gavage (2way ANOVA, 73% total variation, p<0.0001) and surgery mice (2-way ANOVA, 60.47%
total variance, p=0.0005). Tamoxifen treatment and drug delivery protocol did not appear
to impact results with both groups exhibiting a typical sleep/wake cycle.
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When compiling void frequency data of control mice together under their respective
treatment protocol we can observe if the difference in procedure may have impacted
voiding activity without tamoxifen (Figure23). At 4 weeks and pre procedure mice of both
groups have no significant difference in voiding frequency (unpaired student’s t-test,
p=0.1526). After receiving either oral gavage or surgery a differentiation develops between
the two protocol groups at 8 weeks (unpaired student’s t-test, p=0.0041) and 12 week
(unpaired student’s t-test, p=0.0062) with gavage mice displaying markedly higher voiding
events per day. From this data we observe a significant difference in micturition behavior
with the only difference being the method of intervention.
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A

B

C

Fig 18. Urovoid Analyis of Floxed Kcnj2 Mice. A. Mice receiving tamoxifen via subcutaneous
pellet have decreased void mass at maturity that correlates with decreased inter-micturition interval
as seen in C. B. Urine production rate appears consistent despite some variance indicating normal
kidney function between controls and KO mice. Baseline data at 4 weeks is absent for drug
treatment group due to disrupted experiment.
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B

A

Fig 19. Protocol Comparison Void Mass. Mice grouped on method of tamoxifen administration.
A. Void mass remains at consistent levels as mice age in the gavage treatment group. B. Surgery
group are differentiated from gavage with increasing void mass with mouse maturation. Gavage:
Sham n=4, Tamoxifen n=3 Surgery: Sham n=4, Tamoxifen n=4
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A

B

Fig 20. Protocol Comparison Inter-Micturition Interval (IMI). Mice grouped on method of
tamoxifen administration. A. IMI remains consistent as mice age regardless if the gavage
treatment contained tamoxifen. B. More appreciable differences in IMI are noticeable between
drug and surgery groups in 12-week-old mice. Gavage: Sham n=4, Tamoxifen n=3 Surgery: Sham
n=4, Tamoxifen n=4
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B

Figure 21. Protocol Comparison Urine Production Rate (UPR): Mice grouped on method of
tamoxifen administration. A. UPR appears to progress physiologically with aging with no
appreciable differences between mice receiving tamoxifen and shams. B. No differences in UPR
between sham and drug surgery groups noted, however a depreciation in UPR is noticeable in 12week-old mice is apparent.
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B

Figure 22. Protocol Comparison of Voiding Activity During Sleep-Wake Cycle. Mice grouped
on method of tamoxifen administration with voiding events subcategorized based on treatment
group and time of day. A. Gavage mice displayed higher frequency of voids during wake periods
compared to surgery mice B at 8 and 12 weeks of age. Mice from both treatment protocols
demonstrated significant difference in number of voiding events between periods of wakefulness
and rest in a cyclic nature.
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Figure 23: Comparison of Void Frequency per Day of Control KIR2.1SMKO Mice Across Age. A. At
4 weeks old mice of both surgery and gavage groups display similar micturition frequency. B. After
procedure gavage mice display significantly higher voiding frequency than their surgery counterparts.
C. This development of higher voiding frequency in gavage mice over surgery mice is maintained long
after the procedure.
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Discussion
On the surface, presuming the Cre recombinase KO of KIR2.1 was successful using
either method of tamoxifen delivery (which we are not able to verify ex post facto), the
data is not indicative that preventing KIR2.1-mediated hyperpolarization of vascular
smooth muscle is solely capable of causing increased micturition indicative of overactive
bladder. However, multiple aspects of the study underwent substantive changes or lacked
important controls indicating further research is required.
Firstly, the lack of definitive genetic analysis of KIR2.1 knockout from these mice
post-experiment meant we could not verify successful KO of KIR2.1 in the bladder
vasculature. Thus, our observations could be more indicative of physiological differences
unrelated to the gene’s ablation. Repeating this study would include verifying successful
KO of KIR2.1 by measuring for Ba2+-sensitive K+ currents in isolated bladder arteriolar
smooth muscle cells which has been demonstrated previously[1]. Here we would expect
vascular smooth muscle from our KO to lose its signature reduction in K+ currents seen in
control mice with application of Ba2+ and we could thus verify successful ablation.
Secondly, the use of both subcutaneous pellet implantation and oral gavage
introduced variance between treatment groups when the two methods were expected to be
equivalent in their effectiveness. Sham and tamoxifen treatment groups in mice receiving
oral gavage displayed less variance compared with mice receiving pellet implantation.
However the use of oral gavage alone without tamoxifen resulted in higher voiding
frequency than surgery control mice. This suggests the possibility of an environmental
stressor from the procedure that effectively overpowered any appreciable impact we may
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see from KIR2.1 KO. Unlike the subcutaneous pellet, which is a one-time intervention
under anesthesia, the gavage treatment requires multiple dosages during which an
esophageal tube was inserted into awake mice once daily for five consecutive days. This
could be a source of increased stress in these animals verses the surgery groups explaining
the deviation towards increased IMI with smaller voids. It is also worth noting the
effectiveness of tamoxifen-induced KO of KIR2.1 via oral gavage has not been established
in these mice in prior studies while also noting the potential for poor bolus retention in
mice not under anesthesia[70].
Finally, it is important when conducting any long-term conscious behavioral
experiments with the UroVoid to thoroughly screen the environment for potential stressors.
The design of the UroVoid is to provide maximum comfort while isolating voiding activity
of a single animal from potential interference, but this alone cannot ensure the data is
representative of baseline activity. Ambient sounds, vibrations, and changes in temperature
& humidity can all be factors in altering observed behavior. While temperature, humidity,
and day/night cycle were controlled throughout each experiment, the mice could have been
influenced by intermittent disturbances such as the regular activation of the humidifier and
HVAC systems, researcher activity next door, and behavior from other mice from
consecutively running experiments in the same room. All of this is to emphasize the
importance of selecting the appropriate experiment environment prior to UroVoid set up
for later research.
The scope of the project did not include methods of evaluating the effect of
environmental and social stress. While we did not actively seek to introduce stress as a
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variable, quite the opposite, we are unable to rule out its impact or lack thereof. Biomarkers
of chronic stress such as blood serum corticosterone levels could be assayed from every
mouse at the completion of UroVoid trials and compared with similar aged control mice
[71].

Ex Vivo bladder analysis would search for physiological indicators of stress

remodeling including increased bladder volume, afferent nerve activity, and bladder
compliance at low intravesical pressures[59]. Less invasive strategies of determining stress
could also be utilized between UroVoid experiments such as observing mice for motivated
behaviors such as burrowing and nest building as mentioned earlier[67]. Regardless any
future UroVoid studies should not exclude stress evaluation as a staple component given
its consequence can be difficult to fully account for.
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Conclusion
This research set out to determine whether the removal of a key inward rectifier
KIR2.1 from the urinary bladder vasculature resulted in increased urinary frequency
representing OAB pathology. To this end we were not able to demonstrate a definitive
departure in behavior when comparing KO mice with their controls. Identifying nuanced
similarities and differences between treatment groups as well as the limitations of the new
UroVoid system began to dominate the focus of the research as it became clearer our
observations had more factors to them than we had originally accommodated for. Prior
work had demonstrated use of Cre-lox system as well as low-dose tamoxifen
administration through various routes to be reliable means of inducible knockout of KIR2.1,
but this is irrespective of any behavioral impact the dosing procedure may have on the
animal. Our data suggests further behavioral studies evaluating voiding activity after
invasive procedures (gavage, pellet implant) in absence of drugs should be conducted to
establish a baseline. The absence of genotyping controls post experiment was a significant
omission and should be included in any future study using gene knockout. Additionally,
further behavioral observations should be done with the UroVoid under numerous
environmental conditions (ambient noise, lighting, temperature, humidity) to establish
significance of potential confounding factors and their impact on data collection. We
suggest thorough vetting of any proposed experiment environment with control animals
prior to any use of the UroVoid regardless. Rather than assuming social and environmental
stresses can be sufficiently resolved within experimental design, we suggest embracing that
stress is an integral component of any experiment utilizing conscious mice and collecting
additional data on stress related indicators is an absolute necessity. Both procedural
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optimization and thorough behavioral baselining will lend itself toward a more resolute
claim for KIR2.1’s impact on micturition activity, one way or another
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